Popular on PrZen
- L2 Aviation Names Human Resource Veteran Warren Orr as Human Resources Leader - 319
- Lado releases "A Shiny New Toy"
- Bid Ops Partners With Marcus Evans To Announce Optimal: The AI Conference for Procurement Teams
- 83bar, the Patient Activation company, expands business development team
- Contracting Resources Group, Inc. Receives 2020 - 2021 Great Place to Work Certification
- Rock Artist JIGI Is Back With a Jazz Rendition Of "Welcome (II V I)"
- Financial Solutions Inc. Receives the 2020 Best of Sheridan Wyoming Award
- State of Writing 2021 examines how to improve writing ROI
- Intern Pursuit Partnership with Cornell Radio To Expand Intern Whisperer Podcast
- Introducing EbooksCheaper.com - One Stop Shop For Quality eBooks At Slashed Prices
Similar on PrZen
- Grassroots Advocacy Group Urges Biden Administration to Appoint a Doctoral Level Mental Health Professional to Lead SAMHSA
- AUA College of Medicine Establishes Admissions Agreement with Mississippi Valley State University
- Swaggerty's Receives Highest Possible Grade from BRC Food Safety Auditors for 8th Consecutive Year
- Be an Example, Get the Covid Shot
- Former CEO & Founder of Five Star Custom Foods, Acquired by Cargill, Joins CEO Coaching International
- Why Medical Massage Means More Guarantees of Pain Relief for Massage Patients in Los Angeles
- Love vs. Design Launches With Instantly Customizable Peel And Stick Wallpapers For Your Home
- NEAT Elite Glass Now Available Worldwide
- Thomas Mitchiner Law--Unraveling the complexities of Employment Law
- Green Health Eugene and COVID Information
NanoRX Publishes New Research Paper: Metadichol® an anti-viral agent against SARS-COV-2
PrZen/33347712
CHAPPAQUA, N.Y. - PrZen -- Metadichol®, a nano lipid formulation of long chain alcohols, has been shown in vitro studies to be an anti-viral for SARS-COV-2 (the COVID-19 virus) and it does so by blocking the cell entry points for SARS-COV-2. The receptor ACE2 is used by the virus for entry and the serine protease TMPRSS2 for S protein priming. It inhibits both ACE2 and TMPRSS2. An anti-viral assay against the virus using CACO2 cells showed that it had an EC90 of 0.16 µg/ml, which means it effectively eliminates the virus at a very low concentration.
Metadichol® inhibits TMPRSS2 (EC50 of 96 ng/ml). It is 270 times more potent than another another well known inhibitor Camostat mesylate, which has EC50 of (26000 ng/ml). Metadichol is also a moderate inhibitor of ACE2 with an EC50 of 31 µg/ml. Moderate inhibition of ACE2 allows it to perform its key functions in the body, yet fend off SARS-COV-2 entry to the cell. ACE2 lowers blood pressure, regulates intestinal neutral amino acid transport. ACE2 expression and function is increasingly recognized as a potential therapeutic strategy in hypertension and cardiovascular disease, diabetes, lung injury, and fibrotic disorders.
Metadichol, by binding to the Vitamin D receptor (VDR), acts on proteases like Furin and Adam-17, which activate the S-protein spikes for viral spread and pathogenesis in the infected hosts. In Malaria, CD147, also known as Basigin, is used by parasites to gain entry into the cell. Recent publications suggest that it also can be used as a point of entry by the SARS-COV-2 virus. Our previous work (US patent 9,006,292) showed that Metadichol is also potent against Malarial parasites and, by association, CD147. All these results and others are documented in our recent publication available at (https://www.researchsquare.com/article/rs-34021/v1)
A pilot study (outside the USA) on five COVID-19 patients with minor symptoms showed the absence of a virus after 2-4 days of Metadichol @ 20 mg per day. To validate this further, we have initiated a study in collaboration with government agencies. The initial study of 30 patients showed 75% of the patients cleared of the SARS-COV-2 virus after 4 days of treatment - see http://nanorxeurope.com/Documents/India-hospital-letter.pdf.
Metadichol is a safe, non-toxic product made from renewable sources and commercially available with no reported side effects. This unique property allows for the use of Metadichol in a situation that exists today and also to prevent future occurrence of SARS-COV-2 and other infections, and use of it worldwide would allow normal human activity everywhere.
Patent details and publications can be found at https://www.researchgate.net/profile/Palayakotai_Raghavan.
Metadichol, marketed as Nano Soma can be found at www.thenanosoma.com and http://www.nanosoma.net, whilst Nano-Ojas can be found at www.nanoojas.net and Metadichol at www.gen100.com.
Metadichol is available as an oral or topical spray, a topical (or oral) gel and a face cream.
For further information contact:
media_relations@nanorxeurope.com
+1 443 769 1752 (USA)
+44 1212 840 929 (UK)
+61 3 9021 6920 (AUSTRALIA)
+31 30 808 045 (HOLLAND)
+91 98194 85080 (INDIA)
Metadichol® inhibits TMPRSS2 (EC50 of 96 ng/ml). It is 270 times more potent than another another well known inhibitor Camostat mesylate, which has EC50 of (26000 ng/ml). Metadichol is also a moderate inhibitor of ACE2 with an EC50 of 31 µg/ml. Moderate inhibition of ACE2 allows it to perform its key functions in the body, yet fend off SARS-COV-2 entry to the cell. ACE2 lowers blood pressure, regulates intestinal neutral amino acid transport. ACE2 expression and function is increasingly recognized as a potential therapeutic strategy in hypertension and cardiovascular disease, diabetes, lung injury, and fibrotic disorders.
Metadichol, by binding to the Vitamin D receptor (VDR), acts on proteases like Furin and Adam-17, which activate the S-protein spikes for viral spread and pathogenesis in the infected hosts. In Malaria, CD147, also known as Basigin, is used by parasites to gain entry into the cell. Recent publications suggest that it also can be used as a point of entry by the SARS-COV-2 virus. Our previous work (US patent 9,006,292) showed that Metadichol is also potent against Malarial parasites and, by association, CD147. All these results and others are documented in our recent publication available at (https://www.researchsquare.com/article/rs-34021/v1)
A pilot study (outside the USA) on five COVID-19 patients with minor symptoms showed the absence of a virus after 2-4 days of Metadichol @ 20 mg per day. To validate this further, we have initiated a study in collaboration with government agencies. The initial study of 30 patients showed 75% of the patients cleared of the SARS-COV-2 virus after 4 days of treatment - see http://nanorxeurope.com/Documents/India-hospital-letter.pdf.
Metadichol is a safe, non-toxic product made from renewable sources and commercially available with no reported side effects. This unique property allows for the use of Metadichol in a situation that exists today and also to prevent future occurrence of SARS-COV-2 and other infections, and use of it worldwide would allow normal human activity everywhere.
Patent details and publications can be found at https://www.researchgate.net/profile/Palayakotai_Raghavan.
Metadichol, marketed as Nano Soma can be found at www.thenanosoma.com and http://www.nanosoma.net, whilst Nano-Ojas can be found at www.nanoojas.net and Metadichol at www.gen100.com.
Metadichol is available as an oral or topical spray, a topical (or oral) gel and a face cream.
For further information contact:
media_relations@nanorxeurope.com
+1 443 769 1752 (USA)
+44 1212 840 929 (UK)
+61 3 9021 6920 (AUSTRALIA)
+31 30 808 045 (HOLLAND)
+91 98194 85080 (INDIA)
Source: NanoRX Inc.
0 Comments
Latest on PrZen
- Thirteen MBK Senior Living Communities Receive "2021 Best of Senior Living" Distinction
- Grassroots Advocacy Group Urges Biden Administration to Appoint a Doctoral Level Mental Health Professional to Lead SAMHSA
- AUA College of Medicine Establishes Admissions Agreement with Mississippi Valley State University
- Dollyhood Records Signs Distribution Deal With Sony!
- West Coast Recording Artist, Composer and Actor, Blue Ragg$ Releases New Music & Theatrical Video
- Swaggerty's Receives Highest Possible Grade from BRC Food Safety Auditors for 8th Consecutive Year
- Be an Example, Get the Covid Shot
- Former CEO & Founder of Five Star Custom Foods, Acquired by Cargill, Joins CEO Coaching International
- Thiel College names Terry Eddy to Board of Trustees
- Dead Sea Mud Cosmetics Market Report 2017-2030 by Goldstein Market Intelligence
- Beauty Devices Market Report 2017-2030 by Goldstein Market Intelligence
- Hair Color Market Report 2017-2030 by Goldstein Market Intelligence
- "Diamond Fuji" to be Seen from TOKYO SKYTREE in February
- Texpak Offers Environmentally-Friendly Ecotach™ Fasteners to Address Sustainability Needs
- Morningstar names Quantified STF Fund top-performing tactical-allocation fund in 2020
- Financial Solutions Inc. Receives the 2020 Best of Sheridan Wyoming Award
- SHELTER, New Works by Artists Byron Keith Byrd, Stefani Byrd, and Fenix Gallery Collective, January 20–February 24, 2021
- AI.Reverie Awarded $950 Million IDIQ Contract for U.S. Air Force Advanced Battle Management System (ABMS)
- Updated ASI Book Helps Association Executives Improve Organizational Performance Now and Post-COVID
- Song & Music Video "Glory of History" by The ZYG 808 Explores Hypocrisy of Presidential Elections